PMID- 36238842
OWN - NLM
STAT- PubMed-not-MEDLINE
LR  - 20221015
IS  - 1792-1082 (Electronic)
IS  - 1792-1074 (Print)
IS  - 1792-1074 (Linking)
VI  - 24
IP  - 4
DP  - 2022 Oct
TI  - Feasibility and safety of platinum-doublet therapy in patients with small-cell 
      lung cancer in the third-line setting: A multi-institutional retrospective study.
PG  - 368
LID - 10.3892/ol.2022.13488 [doi]
LID - 368
AB  - Small-cell lung cancer (SCLC) is a highly malignant tumor, and no standard 
      third-line therapy has been established. The present study retrospectively 
      analyzed the efficacy and safety of platinum-based regimens in patients with 
      third-line SCLC who received third-line chemotherapy. The association of regimen 
      type with overall survival (OS) or time to treatment failure (TTF) was evaluated 
      using the Cox hazard proportional method, including well-known covariates 
      affecting the prognosis of SCLC. TTF and OS analyses were conducted using the 
      Kaplan-Meier method. The data cutoff date was June 30, 2020. As a result, from 
      January 2015 to August 2019, 111 patients were diagnosed with SCLC, and 37 
      received third-line chemotherapy. Subsequently, 15 patients received a 
      platinum-doublet regimen, and 22 patients received a single-agent regimen. Only 
      the type of regimen was significantly associated with TTF in univariate analysis 
      (odds ratio, 0.44; 95% confidence interval, 0.20-0.95; P=0.03). There were no 
      significant factors associated with OS. The median TTF of patients receiving a 
      platinum-doublet regimen and those receiving a single-agent regimen were 3.9 and 
      2.3 months, respectively (P=0.03). The overall response rates of the 
      platinum-doublet and single-agent regimens were 20.0 and 4.5%, respectively. 
      Similarly, the disease control rates were 73.3 and 36.4% for platinum-doublet and 
      single-agent regimens, respectively. There was a tendency for adverse events 
      (AEs) with any grade to occur more often in platinum-based regimens compared with 
      in single-agent regimens. Severe AEs of grade 3 or higher were observed more 
      often in the platinum-based regimen, especially in myelosuppression. In 
      conclusion, the present study demonstrated the feasibility and safety of 
      platinum-doublet regimens in patients with SCLC in a third-line setting 
      (Registration no. 2020-048. Date of registration, June 5, 2020).
CI  - Copyright: (c) Fukushima et al.
FAU - Fukushima, Takashi
AU  - Fukushima T
AD  - Department of Respiratory Medicine, Hirosaki University Graduate School of 
      Medicine, Hirosaki, Aomori 036-8562, Japan.
FAU - Makiguchi, Tomonori
AU  - Makiguchi T
AD  - Department of Respiratory Medicine, Hirosaki University Graduate School of 
      Medicine, Hirosaki, Aomori 036-8562, Japan.
FAU - Tanaka, Yusuke
AU  - Tanaka Y
AD  - Department of Respiratory Medicine, Hirosaki University Graduate School of 
      Medicine, Hirosaki, Aomori 036-8562, Japan.
FAU - Chubachi, Kei
AU  - Chubachi K
AD  - Department of Respiratory Medicine, Hirosaki University Graduate School of 
      Medicine, Hirosaki, Aomori 036-8562, Japan.
FAU - Ishidoya, Mina
AU  - Ishidoya M
AD  - Department of Respiratory Medicine, Hirosaki University Graduate School of 
      Medicine, Hirosaki, Aomori 036-8562, Japan.
FAU - Suzuki, Sachio
AU  - Suzuki S
AD  - Department of Respiratory Medicine, Hirosaki University Graduate School of 
      Medicine, Hirosaki, Aomori 036-8562, Japan.
FAU - Tanaka, Hisashi
AU  - Tanaka H
AD  - Department of Respiratory Medicine, Hirosaki University Graduate School of 
      Medicine, Hirosaki, Aomori 036-8562, Japan.
FAU - Taima, Kageaki
AU  - Taima K
AD  - Department of Respiratory Medicine, Hirosaki University Graduate School of 
      Medicine, Hirosaki, Aomori 036-8562, Japan.
FAU - Hasegawa, Yukihiro
AU  - Hasegawa Y
AD  - Department of Respiratory Medicine, Aomori Prefectural Central Hospital, Aomori, 
      Aomori 030-8553, Japan.
FAU - Okudera, Koichi
AU  - Okudera K
AD  - Department of Respiratory Medicine, Hirosaki Central Hospital, Hirosaki, Aomori 
      036-8188, Japan.
FAU - Tasaka, Sadatomo
AU  - Tasaka S
AD  - Department of Respiratory Medicine, Hirosaki University Graduate School of 
      Medicine, Hirosaki, Aomori 036-8562, Japan.
LA  - eng
PT  - Journal Article
DEP - 20220901
PL  - Greece
TA  - Oncol Lett
JT  - Oncology letters
JID - 101531236
PMC - PMC9494349
OTO - NOTNLM
OT  - feasibility
OT  - platinum-doublet
OT  - single-agent
OT  - small-cell lung cancer
OT  - third-line
COIS- The authors declare that they have no competing interests.
EDAT- 2022/10/15 06:00
MHDA- 2022/10/15 06:01
PMCR- 2022/09/01
CRDT- 2022/10/14 03:12
PHST- 2022/06/16 00:00 [received]
PHST- 2022/08/18 00:00 [accepted]
PHST- 2022/10/14 03:12 [entrez]
PHST- 2022/10/15 06:00 [pubmed]
PHST- 2022/10/15 06:01 [medline]
PHST- 2022/09/01 00:00 [pmc-release]
AID - OL-24-04-13488 [pii]
AID - 10.3892/ol.2022.13488 [doi]
PST - epublish
SO  - Oncol Lett. 2022 Sep 1;24(4):368. doi: 10.3892/ol.2022.13488. eCollection 2022 
      Oct.